Ferric Carboxymaltose interactions
Full monograph for Ferric CarboxymaltoseCheck it against another medicine
Medicines
33 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Erdafitinib | Major | Others | Coadministration with agents that can alter serum phosphate levels may affect the initial dosage determination of erdafitinib. The mechanism appears to be… | 1 sources — open the full entry |
| Amlodipine Besilate + Benazepril Hydrochloride | Moderate | Others | Limited data suggest that ACE inhibitors may increase the risk and/or severity of systemic adverse effects associated with parenteral administration of iron… | 8 sources — open the full entry |
| Beclomethasone Dipropionate + Chloramphenicol + Clotrimazole + Lidocaine | Moderate | Antagonism | Chloramphenicol can cause bone marrow depression and inhibit red blood cell maturation, which may interfere with the therapeutic effects of iron or vitamin B12… | 3 sources — open the full entry |
| Beta carotene + Vitamin C + Vitamin E | Moderate | Antagonism | Limited data suggest that vitamin E may diminish the therapeutic response to iron therapy in patients with iron deficiency anemia. | 2 sources — open the full entry |
| Captopril | Moderate | Others | Limited data suggest that ACE inhibitors may increase the risk and/or severity of systemic adverse effects associated with parenteral administration of iron… | 8 sources — open the full entry |
| Carbonyl Iron + Folic Acid | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 4 sources — open the full entry |
| Carbonyl Iron + Folic Acid + Zinc Sulfate | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 4 sources — open the full entry |
| Carbonyl Iron + Folic Acid + Zinc Sulfate + Vitamin B Complex + Vitamin C | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 4 sources — open the full entry |
| Chloramphenicol (Oral) | Moderate | Antagonism | Chloramphenicol can cause bone marrow depression and inhibit red blood cell maturation, which may interfere with the therapeutic effects of iron or vitamin B12… | 3 sources — open the full entry |
| Chloramphenicol + Lidocaine Hydrochloride | Moderate | Antagonism | Chloramphenicol can cause bone marrow depression and inhibit red blood cell maturation, which may interfere with the therapeutic effects of iron or vitamin B12… | 3 sources — open the full entry |
| Dexamethasone + Chloramphenicol | Moderate | Antagonism | Chloramphenicol can cause bone marrow depression and inhibit red blood cell maturation, which may interfere with the therapeutic effects of iron or vitamin B12… | 3 sources — open the full entry |
| Enalapril Maleate | Moderate | Others | Limited data suggest that ACE inhibitors may increase the risk and/or severity of systemic adverse effects associated with parenteral administration of iron… | 8 sources — open the full entry |
| Ethinyl Estradiol + Levonorgestrel + Ferrous Fumarate | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 4 sources — open the full entry |
| Ferric Maltol | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 5 sources — open the full entry |
| Ferrous Fumarate + Folic acid | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 4 sources — open the full entry |
| Iron + Folic Acid + Vitamin A + Vitamin C + Zinc | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 4 sources — open the full entry |
| Iron + Folic acid + Vitamin B complex + Vitamin C | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 4 sources — open the full entry |
| Iron + Folic Acid + Vitamin B Complex + Vitamine C + Zinc Sulfate | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 4 sources — open the full entry |
| Iron Polymaltose Complex | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 5 sources — open the full entry |
| Iron Polymaltose Complex + Folic Acid + Zinc + Vitamin B-Complex | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 5 sources — open the full entry |
| Iron Polymaltose Complex + Folic Acid + Zinc Sulfate | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 5 sources — open the full entry |
| Iron Polymaltose Complex + Vitamin B Complex + Zinc | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 5 sources — open the full entry |
| Lisinopril | Moderate | Others | Limited data suggest that ACE inhibitors may increase the risk and/or severity of systemic adverse effects associated with parenteral administration of iron… | 8 sources — open the full entry |
| Norgestrel + Ethinyl Estradiol + Ferrous Fumarate | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 4 sources — open the full entry |
| Perindopril + Indapamide | Moderate | Others | Limited data suggest that ACE inhibitors may increase the risk and/or severity of systemic adverse effects associated with parenteral administration of iron… | 8 sources — open the full entry |
| Perindopril Arginine | Moderate | Others | Limited data suggest that ACE inhibitors may increase the risk and/or severity of systemic adverse effects associated with parenteral administration of iron… | 8 sources — open the full entry |
| Perindopril Arginine + Amlodipine | Moderate | Others | Limited data suggest that ACE inhibitors may increase the risk and/or severity of systemic adverse effects associated with parenteral administration of iron… | 8 sources — open the full entry |
| Ramipril | Moderate | Others | Limited data suggest that ACE inhibitors may increase the risk and/or severity of systemic adverse effects associated with parenteral administration of iron… | 8 sources — open the full entry |
| Ramipril + Hydrochlorothiazide | Moderate | Others | Limited data suggest that ACE inhibitors may increase the risk and/or severity of systemic adverse effects associated with parenteral administration of iron… | 8 sources — open the full entry |
| Tea Tree Oil + Geothermal Water + Vitamin E | Moderate | Antagonism | Limited data suggest that vitamin E may diminish the therapeutic response to iron therapy in patients with iron deficiency anemia. | 2 sources — open the full entry |
| Vitamin B12 + Elemental Iron + Folic Acid | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 4 sources — open the full entry |
| Vitamin C + Vitamin E | Moderate | Antagonism | Limited data suggest that vitamin E may diminish the therapeutic response to iron therapy in patients with iron deficiency anemia. | 2 sources — open the full entry |
| Vitamin C + Vitamin E + Lutein + Copper + Zinc | Moderate | Antagonism | Limited data suggest that vitamin E may diminish the therapeutic response to iron therapy in patients with iron deficiency anemia. | 2 sources — open the full entry |
Conditions
Conditions in which Ferric Carboxymaltose needs care, as documented in this source.
Hypersensitivity, Immediate
ModerateSerious hypersensitivity reactions, including anaphylaxis- type reactions, some of which have been life-threatening have been reported in patients using some injection iron products. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. These products should be administered cautiously, especially in patients with a history of significant allergies. Patients should be monitored during and at least 30 minutes after the administration. Epinephrine should be immediately available in the event of acute hypersensitivity reactions.
2 sources
- "Product Information. Feraheme (ferumoxytol)." Alza Pharmaceuticals (2009):
- "Product Information. Injectafer (ferric carboxymaltose)." American Regent Laboratories Inc (2013):
Hypertension
ModerateTransient elevation of blood pressure has been reported in clinical trials in patients receiving ferric carboxymaltose. These elevations generally occurred immediately after dosing and resolved in 30 minutes. Patients should be monitored for symptoms or signs of hypertension following treatment.
1 source
- "Product Information. Injectafer (ferric carboxymaltose)." American Regent Laboratories Inc (2013):
Hypophosphatemia
ModeratePatients with malabsorption of fat-soluble vitamins or phosphate, or using medications affection proximal renal tubular function, hyperparathyroidism, vitamin D deficiency, or malnutrition may experience symptomatic hypophosphatemia. Cases occur mostly after repeat exposure. Most cases resolved within 3 months. Monitor serum phosphate in at risk patiens requiring repeat treatment.
1 source
- "Product Information. Injectafer (ferric carboxymaltose)." American Regent Laboratories Inc (2013):
Therapeutic duplication
Drug classes that overlap with Ferric Carboxymaltose, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.
iron preparations
The recommended maximum number of medicines in the 'iron preparations' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'iron preparations' category.
Example product in the source data (US market): Ferrous fumarate/iron polysaccharide
iron preparations
The recommended maximum number of medicines in the 'iron preparations' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'iron preparations' category.
Example product in the source data (US market): Hemocyte-f
iron preparations
The recommended maximum number of medicines in the 'iron preparations' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'iron preparations' category.
Example product in the source data (US market): Vitron-c